KRAS and lung cancer: Our results indicate that the levels of KRAS or EGFR mutation in plasma are positively correlated with cfDNA in plasma, and the selection of different blood sampling time points is particularly important, suggesting the independent diagnostic and prognostic value of EGFR and KRAS mutation in the plasma of early lung cancer patients.